A Phase II Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplant for the Treatment of Patients with Hematologic Malignancies Using Busulfan, Fludarabine, and Total Body Irradiation

Principal Investigator

Richard Maziarz

Study Purpose

This study uses a reduced dose of chemotherapy and radiation (called a non-myeloablative transplant) prior to stem cell or bone marrow transplant. This study will examine whether adding Busulfan to the established chemotherapy for reduced intensity transplant (currently at OHSU this standard is Fludarabine and TBI) is safe and effective.

Medical Condition(s)

Multiple disease sites

Eligibility Criteria

* Subjects must either not be eligible or refuse a conventional allogeneic stem cell transplant.
* Subjects will not be allowed to receive myelosuppressive chemotherapy for three weeks prior to conditioning.
* Subjects with hematologic malignancies treatable with a stem cell transplant or with a B cell malignancy except those curable with autologous transplant will be included (ALL/AML/CML/CLL/MDS/MM).
* Subjects will be aged 18-75 years
* Subjects' medical history will be reviewed in detail for study eligibility.

Age Range

18 - 80

Healthy Volunteers Needed


Duration of Participation

Minors Included



Clinical Trials Information Line: Phone 503-494-1080 or trials@ohsu.edu


OHSU Knight Cancer Institute

Recruitment End

Compensation Provided


Go Back